Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Fats, Friends or Foes : Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease. / Ameen, Aishat O.; Freude, Kristine; Aldana, Blanca I.

In: Biomedicines, Vol. 10, No. 11, 2778, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ameen, AO, Freude, K & Aldana, BI 2022, 'Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease', Biomedicines, vol. 10, no. 11, 2778. https://doi.org/10.3390/biomedicines10112778

APA

Ameen, A. O., Freude, K., & Aldana, B. I. (2022). Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease. Biomedicines, 10(11), [2778]. https://doi.org/10.3390/biomedicines10112778

Vancouver

Ameen AO, Freude K, Aldana BI. Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease. Biomedicines. 2022;10(11). 2778. https://doi.org/10.3390/biomedicines10112778

Author

Ameen, Aishat O. ; Freude, Kristine ; Aldana, Blanca I. / Fats, Friends or Foes : Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease. In: Biomedicines. 2022 ; Vol. 10, No. 11.

Bibtex

@article{f4bd8ff383124722961afee03a45bafd,
title = "Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer{\textquoteright}s Disease",
abstract = "Characterising Alzheimer{\textquoteright}s disease (AD) as a metabolic disorder of the brain is gaining acceptance based on the pathophysiological commonalities between AD and major metabolic disorders. Therefore, metabolic interventions have been explored as a strategy for brain energetic rescue. Amongst these, medium-chain fatty acid (MCFA) supplementations have been reported to rescue the energetic failure in brain cells as well as the cognitive decline in patients. Short-chain fatty acids (SCFA) have also been implicated in AD pathology. Due to the increasing therapeutic interest in metabolic interventions and brain energetic rescue in neurodegenerative disorders, in this review, we first summarise the role of SCFAs and MCFAs in AD. We provide a comparison of the main findings regarding these lipid species in established AD animal models and recently developed human cell-based models of this devastating disorder",
author = "Ameen, {Aishat O.} and Kristine Freude and Aldana, {Blanca I.}",
year = "2022",
doi = "10.3390/biomedicines10112778",
language = "English",
volume = "10",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "M D P I AG",
number = "11",

}

RIS

TY - JOUR

T1 - Fats, Friends or Foes

T2 - Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease

AU - Ameen, Aishat O.

AU - Freude, Kristine

AU - Aldana, Blanca I.

PY - 2022

Y1 - 2022

N2 - Characterising Alzheimer’s disease (AD) as a metabolic disorder of the brain is gaining acceptance based on the pathophysiological commonalities between AD and major metabolic disorders. Therefore, metabolic interventions have been explored as a strategy for brain energetic rescue. Amongst these, medium-chain fatty acid (MCFA) supplementations have been reported to rescue the energetic failure in brain cells as well as the cognitive decline in patients. Short-chain fatty acids (SCFA) have also been implicated in AD pathology. Due to the increasing therapeutic interest in metabolic interventions and brain energetic rescue in neurodegenerative disorders, in this review, we first summarise the role of SCFAs and MCFAs in AD. We provide a comparison of the main findings regarding these lipid species in established AD animal models and recently developed human cell-based models of this devastating disorder

AB - Characterising Alzheimer’s disease (AD) as a metabolic disorder of the brain is gaining acceptance based on the pathophysiological commonalities between AD and major metabolic disorders. Therefore, metabolic interventions have been explored as a strategy for brain energetic rescue. Amongst these, medium-chain fatty acid (MCFA) supplementations have been reported to rescue the energetic failure in brain cells as well as the cognitive decline in patients. Short-chain fatty acids (SCFA) have also been implicated in AD pathology. Due to the increasing therapeutic interest in metabolic interventions and brain energetic rescue in neurodegenerative disorders, in this review, we first summarise the role of SCFAs and MCFAs in AD. We provide a comparison of the main findings regarding these lipid species in established AD animal models and recently developed human cell-based models of this devastating disorder

U2 - 10.3390/biomedicines10112778

DO - 10.3390/biomedicines10112778

M3 - Journal article

C2 - 36359298

VL - 10

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 11

M1 - 2778

ER -

ID: 324313537